Susan Egbert
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Susan Egbert has a total of 181 co-authors. Here are the top co-authors by number of shared publications:
- Devasahayam Arokia Balaya Rex
Department of Gastroenterology and Hepatology, Mayo Clinic, Rochester, MN 55905, USA
2 shared publications - Jordan R. Hoffman
Science and Mathematics Division, Delta College, 1961 Delta Rd., University Center, MI, USA
2 shared publications - Marnix H. Medema
Bioinformatics Group, Wageningen University & Research, Wageningen, The Netherlands
2 shared publications - Mitja M. Zdouc
Bioinformatics Group, Wageningen University & Research, Droevendaalsesteeg 1, 6708 PB Wageningen, the Netherlands
2 shared publications - Abdullah Tarık Aslan
Faculty of Medicine and Behavioural Sciences, UQ Centre for Clinical Research, University of Queensland, Brisbane, Queensland, Australia; Department of General Medicine, Sunshine Coast University Hospital, Sunshine Coast, Queensland
1 shared publication - Aditya M. Kunjapur
Department of Chemical and Biomolecular Engineering, University of Delaware, Newark, USA
1 shared publication
Latest Publications
- Open Access
- 17 December 2025
- Published by Microbiology Society in Microbial Genomics
- Vol. 11 (12) , 001569
Paired-omics-based exploration and characterization of biosynthetic diversity in lichenized fungi
The increasing demand for novel drug leads requires bioprospecting non-model taxa. Comparative genomics and correlative omics are a fast and efficient method for linking bioactive but genetically orphan natural products to their biosynthetic gene clusters (BGCs) and identifying potentially novel drug leads. Here we implement these approaches for the first systematic comparison of the BGC diversity in lichen-forming fungi (LFF) (comprising 20% of known fungi), prolific but underutilized producers of bioactive natural products. We first identified BGCs from all publicly available LFF genomes (111), encompassing 71 fungal genera and 23 families, and generated BGC similarity networks of each class. We recovered 5,541 BGCs grouped into 4,464 gene cluster families. We used mass spectrometry (MS) and correlative metabolomics to link five MS-identified metabolites – alectoronic acid, alpha-collatolic acid, evernic acid, stenosporic acid and perlatolic acid – to their putative BGCs. We subsequently used MS on an additional 80 species to explore the taxonomic breadth of common lichen compounds, uncovering a strong pattern between specific families and secondary metabolites. We found that (1) ~98% of the BGCs in LFF are putatively novel (uncharacterized to date), (2) lichen metabolic profiles contain a plethora of unidentified metabolites and (3) ribosomal peptide-related BGCs constitute about 20% of the LFF BGC landscape. Our study provides comprehensive insights into the BGC landscape of LFFs, highlighting unique, widespread and previously uncharacterized BGCs. We anticipate that the approach we describe will serve as a baseline for leveraging biosynthetic research in non-model organisms, inspiring further investigations into microbial dark matter.
- 17 December 2025
- Published by Microbiology Society in Microbial Genomics
- Vol. 11 (12) , 001569
Open AccessPaired-omics-based exploration and characterization of biosynthetic diversity in lichenized fungi
The increasing demand for novel drug leads requires bioprospecting non-model taxa. Comparative genomics and correlative omics are a fast and efficient method for linking bioactive but genetically orphan natural products to their biosynthetic gene clusters (BGCs) and identifying potentially novel drug leads. Here we implement these approaches for the first systematic comparison of the BGC diversity in lichen-forming fungi (LFF) (comprising 20% of known fungi), prolific but underutilized producers of bioactive natural products. We first identified BGCs from all publicly available LFF genomes (111), encompassing 71 fungal genera and 23 families, and generated BGC similarity networks of each class. We recovered 5,541 BGCs grouped into 4,464 gene cluster families. We used mass spectrometry (MS) and correlative metabolomics to link five MS-identified metabolites – alectoronic acid, alpha-collatolic acid, evernic acid, stenosporic acid and perlatolic acid – to their putative BGCs. We subsequently used MS on an additional 80 species to explore the taxonomic breadth of common lichen compounds, uncovering a strong pattern between specific families and secondary metabolites. We found that (1) ~98% of the BGCs in LFF are putatively novel (uncharacterized to date), (2) lichen metabolic profiles contain a plethora of unidentified metabolites and (3) ribosomal peptide-related BGCs constitute about 20% of the LFF BGC landscape. Our study provides comprehensive insights into the BGC landscape of LFFs, highlighting unique, widespread and previously uncharacterized BGCs. We anticipate that the approach we describe will serve as a baseline for leveraging biosynthetic research in non-model organisms, inspiring further investigations into microbial dark matter.
- Open Access
- 4 June 2025
- Published by Wiley in Environmental Microbiology
- Vol. 27 (6) , e70112
A Biosynthetic and Taxonomic Atlas of the Global Lichen Holobiont
Lichens are pioneer species in several ecosystems, and as such are found in a variety of geographic regions and environments. Here, inspection of metagenomic data from 794 lichen samples from 34 countries reveals the presence of a complex holobiont harbouring remarkable biosynthetic capabilities, particularly in the bacterial consortia, a component that has been somewhat underappreciated. While bacteria were consistently present, their abundance varied among lichen taxa. Common bacterial genera included Microbacterium , Terribacillus , and JABEUN01 (an Acidimicrobiaceae bacterium awaiting Latin binomial naming assignment) albeit in low abundance. Lichenihabitans and Sphingomonas genera were moderately abundant, present in approximately 30% of samples, and exhibited an enrichment in the number of biosynthetic gene clusters (BGCs) predicted to encode secondary metabolites (biosynthetic potential). We found that both fungal and bacterial biosynthetic repertoires appeared to follow genus‐specific patterns but that there was greater relative homogeneity of BGCs in the fungal genera. The substantial biosynthetic diversity within lichen holobionts is evident in our findings, with the lichen‐associated bacteria emerging as a promising potential source for sustainable drug discovery.
- 4 June 2025
- Published by Wiley in Environmental Microbiology
- Vol. 27 (6) , e70112
Open AccessA Biosynthetic and Taxonomic Atlas of the Global Lichen Holobiont
Lichens are pioneer species in several ecosystems, and as such are found in a variety of geographic regions and environments. Here, inspection of metagenomic data from 794 lichen samples from 34 countries reveals the presence of a complex holobiont harbouring remarkable biosynthetic capabilities, particularly in the bacterial consortia, a component that has been somewhat underappreciated. While bacteria were consistently present, their abundance varied among lichen taxa. Common bacterial genera included Microbacterium , Terribacillus , and JABEUN01 (an Acidimicrobiaceae bacterium awaiting Latin binomial naming assignment) albeit in low abundance. Lichenihabitans and Sphingomonas genera were moderately abundant, present in approximately 30% of samples, and exhibited an enrichment in the number of biosynthetic gene clusters (BGCs) predicted to encode secondary metabolites (biosynthetic potential). We found that both fungal and bacterial biosynthetic repertoires appeared to follow genus‐specific patterns but that there was greater relative homogeneity of BGCs in the fungal genera. The substantial biosynthetic diversity within lichen holobionts is evident in our findings, with the lichen‐associated bacteria emerging as a promising potential source for sustainable drug discovery.
- Top Cited PapersOpen Access
- 4 November 2024
- Published by American Medical Association (AMA) in JAMA Network Open
- Vol. 7 (11) , e2444495
Guidelines for the Prevention, Diagnosis, and Management of Urinary Tract Infections in Pediatrics and Adults
Importance: Traditional approaches to practice guidelines frequently result in dissociation between strength of recommendation and quality of evidence. Objective: To create a clinical guideline for the diagnosis and management of urinary tract infections that addresses the gap between the evidence and recommendation strength. Evidence Review: This consensus statement and systematic review applied an approach previously established by the WikiGuidelines Group to construct collaborative clinical guidelines. In May 2023, new and existing members were solicited for questions on urinary tract infection prevention, diagnosis, and management. For each topic, literature searches were conducted up until early 2024 in any language. Evidence was reported according to the WikiGuidelines charter: clear recommendations were established only when reproducible, prospective, controlled studies provided hypothesis-confirming evidence. In the absence of such data, clinical reviews were developed discussing the available literature and associated risks and benefits of various approaches. Findings: A total of 54 members representing 12 countries reviewed 914 articles and submitted information relevant to 5 sections: prophylaxis and prevention (7 questions), diagnosis and diagnostic stewardship (7 questions), empirical treatment (3 questions), definitive treatment and antimicrobial stewardship (10 questions), and special populations and genitourinary syndromes (10 questions). Of 37 unique questions, a clear recommendation could be provided for 6 questions. In 3 of the remaining questions, a clear recommendation could only be provided for certain aspects of the question. Clinical reviews were generated for the remaining questions and aspects of questions not meeting criteria for a clear recommendation. Conclusions and Relevance: In this consensus statement that applied the WikiGuidelines method for clinical guideline development, the majority of topics relating to prevention, diagnosis, and treatment of urinary tract infections lack high-quality prospective data and clear recommendations could not be made. Randomized clinical trials are underway to address some of these gaps; however further research is of utmost importance to inform true evidence-based, rather than eminence-based practice.
- 4 November 2024
- Published by American Medical Association (AMA) in JAMA Network Open
- Vol. 7 (11) , e2444495
Top Cited PapersOpen AccessGuidelines for the Prevention, Diagnosis, and Management of Urinary Tract Infections in Pediatrics and Adults
Importance: Traditional approaches to practice guidelines frequently result in dissociation between strength of recommendation and quality of evidence. Objective: To create a clinical guideline for the diagnosis and management of urinary tract infections that addresses the gap between the evidence and recommendation strength. Evidence Review: This consensus statement and systematic review applied an approach previously established by the WikiGuidelines Group to construct collaborative clinical guidelines. In May 2023, new and existing members were solicited for questions on urinary tract infection prevention, diagnosis, and management. For each topic, literature searches were conducted up until early 2024 in any language. Evidence was reported according to the WikiGuidelines charter: clear recommendations were established only when reproducible, prospective, controlled studies provided hypothesis-confirming evidence. In the absence of such data, clinical reviews were developed discussing the available literature and associated risks and benefits of various approaches. Findings: A total of 54 members representing 12 countries reviewed 914 articles and submitted information relevant to 5 sections: prophylaxis and prevention (7 questions), diagnosis and diagnostic stewardship (7 questions), empirical treatment (3 questions), definitive treatment and antimicrobial stewardship (10 questions), and special populations and genitourinary syndromes (10 questions). Of 37 unique questions, a clear recommendation could be provided for 6 questions. In 3 of the remaining questions, a clear recommendation could only be provided for certain aspects of the question. Clinical reviews were generated for the remaining questions and aspects of questions not meeting criteria for a clear recommendation. Conclusions and Relevance: In this consensus statement that applied the WikiGuidelines method for clinical guideline development, the majority of topics relating to prevention, diagnosis, and treatment of urinary tract infections lack high-quality prospective data and clear recommendations could not be made. Randomized clinical trials are underway to address some of these gaps; however further research is of utmost importance to inform true evidence-based, rather than eminence-based practice.
- 2 July 2024
- Published by Taylor & Francis in Journal of Pain & Palliative Care Pharmacotherapy
- Vol. 38 (3) , 302-317
Evidence of Commonly Used Integrative Approaches with Pharmacotherapy for Chronic Pain Management
This review examines the integration of traditional pharmacological methods with alternative and complementary therapies in chronic pain management. It delves into neurostimulation techniques, highlighting their clinical outcomes and biological bases. Acupuncture's role in modulating pain pathways is explored, illustrating its balance of tradition and clinical application. The paper also covers the pain-relieving potential of herbal medicine, emphasizing natural products' significance in pain relief. Additionally, it discusses the psychological and rehabilitative dimensions of pain through psychosocial therapy and counseling. The conclusion underscores the importance of a multidisciplinary approach, integrating diverse therapies into conventional pain management to effectively treat chronic pain. This synthesis highlights the synergistic potential of combining traditional and innovative therapeutic modalities, offering a comprehensive guide for healthcare professionals in enhancing pain management practices.
- 2 July 2024
- Published by Taylor & Francis in Journal of Pain & Palliative Care Pharmacotherapy
- Vol. 38 (3) , 302-317
Evidence of Commonly Used Integrative Approaches with Pharmacotherapy for Chronic Pain Management
This review examines the integration of traditional pharmacological methods with alternative and complementary therapies in chronic pain management. It delves into neurostimulation techniques, highlighting their clinical outcomes and biological bases. Acupuncture's role in modulating pain pathways is explored, illustrating its balance of tradition and clinical application. The paper also covers the pain-relieving potential of herbal medicine, emphasizing natural products' significance in pain relief. Additionally, it discusses the psychological and rehabilitative dimensions of pain through psychosocial therapy and counseling. The conclusion underscores the importance of a multidisciplinary approach, integrating diverse therapies into conventional pain management to effectively treat chronic pain. This synthesis highlights the synergistic potential of combining traditional and innovative therapeutic modalities, offering a comprehensive guide for healthcare professionals in enhancing pain management practices.
- Open Access
- 13 November 2023
Comprehensive Overview of Bottom-Up Proteomics using Mass Spectrometry.
Proteomics is the large scale study of protein structure and function from biological systems through protein identification and quantification. "Shotgun proteomics" or "bottom-up proteomics" is the prevailing strategy, in which proteins are hydrolyzed into peptides that are analyzed by mass spectrometry. Proteomics studies can be applied to diverse studies ranging from simple protein identification to studies of proteoforms, protein-protein interactions, protein structural alterations, absolute and relative protein quantification, post-translational modifications, and protein stability. To enable this range of different experiments, there are diverse strategies for proteome analysis. The nuances of how proteomic workflows differ may be challenging to understand for new practitioners. Here, we provide a comprehensive overview of different proteomics methods to aid the novice and experienced researcher. We cover from biochemistry basics and protein extraction to biological interpretation and orthogonal validation. We expect this work to serve as a basic resource for new practitioners in the field of shotgun or bottom-up proteomics.
- 13 November 2023
Open AccessComprehensive Overview of Bottom-Up Proteomics using Mass Spectrometry.
Proteomics is the large scale study of protein structure and function from biological systems through protein identification and quantification. "Shotgun proteomics" or "bottom-up proteomics" is the prevailing strategy, in which proteins are hydrolyzed into peptides that are analyzed by mass spectrometry. Proteomics studies can be applied to diverse studies ranging from simple protein identification to studies of proteoforms, protein-protein interactions, protein structural alterations, absolute and relative protein quantification, post-translational modifications, and protein stability. To enable this range of different experiments, there are diverse strategies for proteome analysis. The nuances of how proteomic workflows differ may be challenging to understand for new practitioners. Here, we provide a comprehensive overview of different proteomics methods to aid the novice and experienced researcher. We cover from biochemistry basics and protein extraction to biological interpretation and orthogonal validation. We expect this work to serve as a basic resource for new practitioners in the field of shotgun or bottom-up proteomics.
- Top Cited PapersOpen Access
- 18 November 2022
- Published by Oxford University Press (OUP) in Nucleic Acids Research
- Vol. 51 (D1) , D603-D610
MIBiG 3.0: a community-driven effort to annotate experimentally validated biosynthetic gene clusters
With an ever-increasing amount of (meta)genomic data being deposited in sequence databases, (meta)genome mining for natural product biosynthetic pathways occupies a critical role in the discovery of novel pharmaceutical drugs, crop protection agents and biomaterials. The genes that encode these pathways are often organised into biosynthetic gene clusters (BGCs). In 2015, we defined the Minimum Information about a Biosynthetic Gene cluster (MIBiG): a standardised data format that describes the minimally required information to uniquely characterise a BGC. We simultaneously constructed an accompanying online database of BGCs, which has since been widely used by the community as a reference dataset for BGCs and was expanded to 2021 entries in 2019 (MIBiG 2.0). Here, we describe MIBiG 3.0, a database update comprising large-scale validation and re-annotation of existing entries and 661 new entries. Particular attention was paid to the annotation of compound structures and biological activities, as well as protein domain selectivities. Together, these new features keep the database up-to-date, and will provide new opportunities for the scientific community to use its freely available data, e.g. for the training of new machine learning models to predict sequence-structure-function relationships for diverse natural products. MIBiG 3.0 is accessible online at https://mibig.secondarymetabolites.org/.
- 18 November 2022
- Published by Oxford University Press (OUP) in Nucleic Acids Research
- Vol. 51 (D1) , D603-D610
Top Cited PapersOpen AccessMIBiG 3.0: a community-driven effort to annotate experimentally validated biosynthetic gene clusters
With an ever-increasing amount of (meta)genomic data being deposited in sequence databases, (meta)genome mining for natural product biosynthetic pathways occupies a critical role in the discovery of novel pharmaceutical drugs, crop protection agents and biomaterials. The genes that encode these pathways are often organised into biosynthetic gene clusters (BGCs). In 2015, we defined the Minimum Information about a Biosynthetic Gene cluster (MIBiG): a standardised data format that describes the minimally required information to uniquely characterise a BGC. We simultaneously constructed an accompanying online database of BGCs, which has since been widely used by the community as a reference dataset for BGCs and was expanded to 2021 entries in 2019 (MIBiG 2.0). Here, we describe MIBiG 3.0, a database update comprising large-scale validation and re-annotation of existing entries and 661 new entries. Particular attention was paid to the annotation of compound structures and biological activities, as well as protein domain selectivities. Together, these new features keep the database up-to-date, and will provide new opportunities for the scientific community to use its freely available data, e.g. for the training of new machine learning models to predict sequence-structure-function relationships for diverse natural products. MIBiG 3.0 is accessible online at https://mibig.secondarymetabolites.org/.
- 28 August 2022
- Published by Elsevier in Fungal Biology
- Vol. 126 (11-12) , 697-706
Unraveling usnic acid: a comparison of biosynthetic gene clusters between two reindeer lichen (Cladonia rangiferina and C. uncialis)
- 28 August 2022
- Published by Elsevier in Fungal Biology
- Vol. 126 (11-12) , 697-706
Unraveling usnic acid: a comparison of biosynthetic gene clusters between two reindeer lichen (Cladonia rangiferina and C. uncialis)